Trial Profile
Phase I, first-in-human, double-blind, randomized, placebo-controlled, single ascending dose investigating the safety and efficacy of ANF-Rho (Pegfilgrastim ANF) in healthy adults
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 01 Aug 2017
Price :
$35
*
At a glance
- Drugs Pegfilgrastim ANF (Primary) ; Pegfilgrastim
- Indications Neutropenia
- Focus Adverse reactions; First in man
- 28 Jul 2017 Results published in the Investigational New Drugs
- 28 Jan 2016 New trial record
- 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology